Скачать или смотреть Tariff Turmoil: Global Pharma Stocks Take a Hit

What happens when a trade war threatens vital medicine imports?
Global pharmaceutical stocks dipped sharply after Trump announced a potential tariff on drug imports, igniting fears across the market.,The tariff threat jeopardizes interconnected global supply chains, raising concerns over pharmaceutical availability and costs.,Despite previous exemptions, the administration's plans suggest levies on an industry traditionally untouched by tariffs are imminent.,Prominent drug companies like Amgen and Pfizer saw shares plunge between 3% and 6% during premarket trading.,European healthcare stocks fell 5%, marking their steepest decline since October 2022 amid escalating tariff fears.,Analysts warn that tariffs won't incentivize local production and may complicate production processes significantly.,The potential impact of tariffs could escalate costs of pharmaceutical imports by $53 billion, burdening consumers and manufacturers alike.,If manufacturers move to the U.S., they may face exorbitant expenses and a lengthy production ramp-up period.,Amidst tariff negotiations, Indian pharma stocks fell almost 2%, with generics forming a critical part of U.S. exports.
#PharmaStocks, #TradeTariffs, #GlobalMarket